The detection and reporting of alterations such as IDH1/2 mutation, 1p/19q co-deletion, EGFR amplification, TERT-promoter mutation, and CDKN2A homozygous loss in the diagnosis of infiltrating glioma has become standard practice in clinical neuropathology. This evidence concerns the gene EGFR and glioma.